Security
Fennec Pharmaceuticals Inc. Common Stock · FENC
FENCNASDAQCommon stockCurrentCIK 1211583Updated Oct 20, 2026
Name history
ADHEREX TECHNOLOGIES INC · through Aug 14, 2014
FENC price & chart
Loading TradingView…
NASDAQ:FENC on TradingView ↗About the company
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.
In the news
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) ↗
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 49,261,000Source | 58,921,000Source | 75,753,000Source | 44,876,000Source | 63,161,000Source | 71,822,000Source | 46,403,000Source | 69,193,000Source | 70,551,000Source | 44,946,000Source | 26,864,000Source | 26,939,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,947,000Source | 40,320,000Source | 41,249,000Source | 18,705,000Source | 43,054,000Source | 40,179,000Source | 22,675,000Source | 51,184,000Source | 36,788,000Source | 26,634,000Source | 13,269,000Source | 23,774,000Source |
| Assets, CurrentUSD | 46,064,000Source | 57,965,000Source | 72,500,000Source | 40,794,000Source | 62,172,000Source | 66,880,000Source | 42,975,000Source | 68,171,000Source | 67,043,000Source | 44,124,000Source | 26,858,000Source | 26,728,000Source |
| Other Assets, NoncurrentUSD | 743,000Source | 956,000Source | 666,000Source | 768,000Source | 989,000Source | 691,000Source | 794,000Source | 1,022,000Source | 717,000Source | 2,438,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 53,753,000Source | 64,092,000Source | 33,311,000Source | 52,339,000Source | 64,518,000Source | 34,147,000Source | 52,283,000Source | 66,179,000Source | 35,079,000Source | 50,818,000Source | 38,486,000Source | 29,508,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 147,652,000Source | 145,438,000Source | 193,190,000Source | 146,165,000Source | 145,281,000Source | 191,229,000Source | 145,979,000Source | 144,934,000Source | 189,906,000Source | 145,608,000Source | 144,307,000Source | 142,591,000Source |
| Retained Earnings (Accumulated Deficit)USD | -224,636,000Source | -217,696,000Source | -227,248,000Source | -223,998,000Source | -211,961,000Source | -229,221,000Source | -220,846,000Source | -206,408,000Source | -229,422,000Source | -219,681,000Source | -219,245,000Source | -203,200,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source | 1,243,000Source |
| Stockholders' Equity Attributable to ParentUSD | -4,492,000Source | -5,171,000Source | 42,442,000Source | -7,463,000Source | -1,357,000Source | 37,675,000Source | -5,880,000Source | 3,014,000Source | 35,472,000Source | -5,872,000Source | -11,622,000Source | -2,569,000Source |
| Additional Paid in Capital, Common StockUSD | 71,249,000Source | 65,844,000Source | 75,257,000Source | 69,127,000Source | 64,080,000Source | 74,424,000Source | 67,744,000Source | 63,245,000Source | 73,745,000Source | 66,958,000Source | 62,073,000Source | 56,797,000Source |
| Liabilities and EquityUSD | 49,261,000Source | 58,921,000Source | 75,753,000Source | 44,876,000Source | 63,161,000Source | 71,822,000Source | 46,403,000Source | 69,193,000Source | 70,551,000Source | 44,946,000Source | 26,864,000Source | 26,939,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,815,000Source | 7,435,000Source | 12,394,000Source | 8,414,000Source | 7,749,000Source | 9,586,000Source | 8,371,000Source | 9,836,000Source | 10,518,000Source | 6,919,000Source | 7,553,000Source | 4,609,000Source |
| Operating Lease, Liability, CurrentUSD | — | 7,000Source | — | — | 12,000Source | — | — | 17,000Source | — | 2,000Source | 21,000Source | — |
| Accounts Payable, CurrentUSD | 5,866,000Source | 3,867,000Source | 5,516,000Source | 5,941,000Source | 4,447,000Source | 6,281,000Source | 5,280,000Source | 5,204,000Source | 4,635,000Source | 3,241,000Source | 3,778,000Source | 2,390,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 2,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,701,000Source | 3,313,000Source | 3,696,000Source | 2,225,000Source | 3,038,000Source | 3,057,000Source | 2,843,000Source | 4,363,000Source | 5,635,000Source | 3,428,000Source | 3,754,000Source | 2,219,000Source |
| Long-term DebtUSD | 19,377,000Source | 32,096,000Source | — | 19,364,000Source | 31,775,000Source | — | 19,351,000Source | 31,349,000Source | — | 19,338,000Source | 30,931,000Source | 24,899,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 201,000Source | -1,165,000Source | -9,741,000Source | -436,000Source | -16,045,000Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 990,000Source | 798,000Source | 7,033,000Source | 5,061,000Source | 5,354,000Source | 4,087,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -4,512,000Source | 5,277,000Source | 12,440,000Source | 7,873,000Source | 7,269,000Source | 1,545,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 291,000Source | 344,000Source | 1,278,000Source | -579,000Source | 1,580,000Source | 576,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,646,000Source | 2,039,000Source | 1,394,000Source | -537,000Source | 1,388,000Source | 1,612,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 2,379,000Source | -4,318,000Source | -12,473,000Source | 26,980,000Source | -17,143,000Source | -18,058,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 311,000Source | 12,000Source | 187,000Source | 176,000Source | 78,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,012,000Source | 359,000Source | 22,627,000Source | -13,615,000Source | 6,638,000Source | 20,732,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 3,000Source | — |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 19,477,000Source | 13,000,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 3,391,000Source | -3,959,000Source | 10,154,000Source | 13,365,000Source | -10,505,000Source | 2,674,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 21,947,000Source | 40,320,000Source | 41,249,000Source | 18,705,000Source | 40,179,000Source | 22,675,000Source | 36,788,000Source | 26,634,000Source | 13,269,000Source | 23,774,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 4,160,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 748,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | 21,000Source | 221,000Source | 132,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 12,000Source | 21,000Source | — | 13,000Source | — | 13,000Source | 64,000Source | 89,000Source | 287,000Source | 149,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | -3,000Source | — | -6,000Source | 17,000Source | -12,000Source | 13,000Source | 28,000Source | -82,000Source | 5,000Source | -9,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -2,022,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 6,752,000Source | 6,121,000Source | 4,639,000Source | 6,526,000Source | 3,186,000Source | 5,865,000Source | 28,294,000Source | 23,053,000Source | 20,585,000Source | 17,722,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 42,000Source | — | — | — | 106,000Source | 365,000Source | — | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 773,000Source | 517,000Source | — | — |
| Investment Income, InterestUSD | — | — | 152,000Source | 516,000Source | 287,000Source | 171,000Source | 339,000Source | 236,000Source | 787,000Source | 1,682,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -638,000Source | -5,735,000Source | 1,973,000Source | -3,152,000Source | 201,000Source | -1,165,000Source | -9,741,000Source | -436,000Source | -16,045,000Source | -23,714,000Source |
| Nonoperating Income (Expense)USD | — | — | -449,000Source | -533,000Source | 278,000Source | -420,000Source | 320,000Source | -357,000Source | -3,353,000Source | -2,639,000Source | -3,274,000Source | -1,125,000Source |
| Operating ExpensesUSD | — | — | 12,651,000Source | 12,176,000Source | 16,137,000Source | 12,384,000Source | 15,227,000Source | 9,559,000Source | 50,924,000Source | 44,970,000Source | 32,764,000Source | 24,038,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | 1,740,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 4,997,000Source | 24,935,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,323,000Source | 371,000Source | 2,190,000Source | 1,301,000Source | 1,716,000Source | 928,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 23,782,000Source | — |
| Stock or Unit Option Plan Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 12,462,000Source | 6,974,000Source | 17,874,000Source | 9,652,000Source | 15,108,000Source | 8,751,000Source | 44,642,000Source | 47,538,000Source | 21,252,000Source | — |
| Cost of RevenueUSD | — | — | — | — | — | — | — | — | — | — | 1,259,000Source | 86,000Source |
| Operating Income (Loss)USD | — | — | -189,000Source | -5,202,000Source | 1,737,000Source | -2,732,000Source | -119,000Source | -808,000Source | -6,282,000Source | 2,568,000Source | -12,771,000Source | -22,589,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | 2,015,000Source | -3,152,000Source | — | — | -9,635,000Source | -71,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 42,000Source | — | — | — | 106,000Source | 365,000Source | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -638,000Source | -5,735,000Source | 1,973,000Source | -3,152,000Source | 201,000Source | -1,165,000Source | -9,741,000Source | -436,000Source | -16,045,000Source | -23,714,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.02Source | -0.21Source | 0.06Source | -0.11Source | 0.01Source | -0.04Source | -0.34Source | -0.02Source | -0.6Source | -0.9Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.02Source | -0.21Source | 0.05Source | -0.11Source | 0.01Source | -0.04Source | -0.34Source | -0.02Source | -0.6Source | -0.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 27,889,000Source | 27,371,000Source | 34,545,000Source | 27,664,000Source | 34,336,000Source | 27,578,000Source | 28,577,000Source | 27,294,000Source | 26,574,000Source | 26,275,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 27,889,000Source | 27,371,000Source | 36,430,000Source | 27,664,000Source | 35,548,000Source | 27,578,000Source | 28,577,000Source | 27,294,000Source | 26,574,000Source | 26,275,000Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 6,752,000Source | 6,121,000Source | 4,639,000Source | 6,526,000Source | 3,186,000Source | 5,865,000Source | 28,294,000Source | 23,053,000Source | 20,585,000Source | 17,722,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 19,993,000Source | 1,449,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -14,327,000Source | — | — | -10,548,000Source |
| Interest Expense, DebtUSD | — | — | 586,000Source | 1,025,000Source | 3,000Source | 594,000Source | 7,000Source | 592,000Source | 2,080,000Source | 4,069,000Source | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 441,000Source | — |
| Investment Income, InterestUSD | — | — | 152,000Source | 516,000Source | 287,000Source | 171,000Source | 339,000Source | 236,000Source | 787,000Source | 1,682,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -449,000Source | -533,000Source | 278,000Source | -420,000Source | 320,000Source | -357,000Source | -3,353,000Source | -2,639,000Source | -3,274,000Source | -1,125,000Source |
| Operating ExpensesUSD | — | — | 12,651,000Source | 12,176,000Source | 16,137,000Source | 12,384,000Source | 15,227,000Source | 9,559,000Source | 50,924,000Source | 44,970,000Source | 32,764,000Source | 24,038,000Source |
| Research and Development ExpenseUSD | — | — | 29,000Source | 97,000Source | 118,000Source | 107,000Source | 49,000Source | 94,000Source | 250,000Source | 307,000Source | 56,000Source | 3,531,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 23,782,000Source | — |
| Selling and Marketing ExpenseUSD | — | — | 5,210,000Source | 4,601,000Source | 10,659,000Source | 4,784,000Source | 11,422,000Source | 3,227,000Source | 18,616,000Source | 18,426,000Source | 12,123,000Source | 2,785,000Source |
Filing attachments
fencf-20260917xex99d1.htm · 8-K · 2026-09-17
EX-99.1 2 fencf-20260917xex99d1.htm EX-99.1 Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK® in Japan AT SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Gra…
Read attachment ↗fencf-20260630xex99d1.htm · 10-Q · 2026-08-13
Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS SECOND Quarter 2026 Financial Results and Provides Business Update ~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue to Validate Commercial Growth Strategy ~ ~ Real-World Evidence Presented at ASCO 2026 Reinforced that PEDMARK® Can Be Easily Integrated in…
Read attachment ↗tm2617383d1_ex99-1.htm · S-8 · 2026-06-11
Exhibit 99.1 FENNEC PHARMACEUTICALS INC. 2020 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Fennec Pharmaceuticals Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Fennec Pharmaceuticals Inc. (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct …
Read attachment ↗fencf-20260521xex99d1.htm · 8-K · 2026-05-22
EX-99.1 2 fencf-20260521xex99d1.htm EX-99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH supporting INTEGRATION AND use of pedmark® at the 2026 ASCO Annual Meeting ~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patien…
Read attachment ↗fencf-20260518xex99d1.htm · 8-K · 2026-05-18
EX-99.1 2 fencf-20260518xex99d1.htm EX-99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) Research Triangle Park, NC, May 18, 2026 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of …
Read attachment ↗fencf-20260331xex99d1.htm · 10-Q · 2026-05-14
Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS First Quarter 2026 Financial Results and Provides Business Update ~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts E…
Read attachment ↗